NCT06166459

Brief Summary

Percutaneous coronary intervention for coronary bifurcation lesions represents one of the most challenging procedures in interventional cardiology because of lower angiographic success rate and increased risk of procedural complications. The study is designed to enroll 200 patients with acute or chronic coronary syndromes that meet the indications for intervention and with angiographic confirmed de novo Medina type 0,1,0 or 0,0,1 bifurcation lesion. In view of the potential risks of using DCB alone in the treatment of de novo bifurcation lesions, the following 2 treatment strategies are available. (1) DCB combined with provisional DES implantation 1-2 mm distally to the lesion ostium whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the lesion ostium followed by DCB (DES+DCB strategy). The primary endpoint was late lumen loss and major adverse cardiovascular events.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P50-P75 for not_applicable coronary-artery-disease

Timeline
Completed

Started Apr 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 12, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

April 22, 2024

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
Last Updated

March 27, 2024

Status Verified

December 1, 2023

Enrollment Period

1.9 years

First QC Date

December 3, 2023

Last Update Submit

March 25, 2024

Conditions

Keywords

drug-coated balloonpercutaneous coronary interventiondrug-eluting stentYao strategy

Outcome Measures

Primary Outcomes (2)

  • late lumen loss

    post-procedural minimum lumen diameter minus follow-up minimum lumen diameter.

    9 months follow-up

  • major adverse cardiovascular events

    include cardiac death, non-fatal myocardial infarction, and target lesion revascularization.

    1 year

Study Arms (1)

Yao technique

EXPERIMENTAL

The following 2 treatment strategies are available. (1) DCB combined with provisional DES implantation 1-2 mm distally to the lesion ostium whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the lesion ostium followed by DCB (DES+DCB strategy).

Procedure: Drug-coated balloon combined with provisional drug-eluting stent implantation

Interventions

(1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).

Yao technique

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects at the age between ≥18 and ≤80 years old;
  • De novo native lesion, Median type 010/001 bifurcation lesion;
  • The reference diameter of the target vessel was 2.75-4.0mm and the length was less than 40mm;
  • Subjects are willing to participate in the study, sign informed consent form, and accept clinical follow-up.

You may not qualify if:

  • The diameter stenosis of adjacent branch vessel ostium ≥50%;
  • Acute ST-segment elevation myocardial infarction;
  • Stents implanted within 10 mm proximal or distal to the target lesion;
  • Aneurysm within 10 mm proximal or distal to the target lesion;
  • There is target vessel distortion or severe calcification lesion, so balloon catheter fails to pass;
  • Previous coronary artery bypass grafting;
  • Evidence for extensive thrombus within target vessel;
  • Evidence of heart failure by at least one of the following: a. Most recent LVEF ≤35%, or b. Current heart failure defined as dyspnea at rest (NYHA class IV assessed day of procedure), or c. Killip class ≥2 (post STEMI patients);
  • Subjects with a life expectancy of ≤1 year;
  • Subjects with stroke, peptic ulcer, or gastrointestinal bleeding within the past 6 months;
  • Subjects with severe renal failure (eGFR\<30ml/minute), failure to comply with angiography conditions;
  • Subjects who are intolerance to aspirin and/or clopidogrel or ticagrelor or have contraindications;
  • Subjects who are intolerance or allergic to heparin, contrast agent;
  • Patients who are participating in the clinical trial of other drug or device without reaching the time limit of primary endpoint;
  • Subjects who are not applicable to be enrolled by investigators due to other reasons.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (10)

  • Escarcega RO. What is the Optimal Technique for Ostial Left Anterior Descending Artery Lesions? Cardiovasc Revasc Med. 2019 Dec;20(12):1063-1064. doi: 10.1016/j.carrev.2019.10.003. Epub 2019 Oct 22. No abstract available.

    PMID: 31669112BACKGROUND
  • Dishmon DA, Elhaddi A, Packard K, Gupta V, Fischell TA. High incidence of inaccurate stent placement in the treatment of coronary aorto-ostial disease. J Invasive Cardiol. 2011 Aug;23(8):322-6.

    PMID: 21828393BACKGROUND
  • Hildick-Smith DJ, Shapiro LM. Ostial left anterior descending coronary artery stent positioning: partial preinflation prevents stent oscillation and facilitates accurate deployment. J Interv Cardiol. 2001 Aug;14(4):439-42. doi: 10.1111/j.1540-8183.2001.tb00355.x.

    PMID: 12053499BACKGROUND
  • Cayli M, Elbasan Z, Gur M, Seker T, Ucar H, Kuloglu O, Sen O, Sahin DY, Kalkan GY. Modified flower petal technique in the treatment of Medina type 0,0,1 or 0,1,0 lesions. EuroIntervention. 2015 Nov;11(7):772-9. doi: 10.4244/EIJV11I7A154.

    PMID: 26603986BACKGROUND
  • Gutierrez-Chico JL, Villanueva-Benito I, Villanueva-Montoto L, Vazquez-Fernandez S, Kleinecke C, Gielen S, Iniguez-Romo A. Szabo technique versus conventional angiographic placement in bifurcations 010-001 of Medina and in aorto-ostial stenting: angiographic and procedural results. EuroIntervention. 2010 Feb;5(7):801-8. doi: 10.4244/eijv5i7a134.

    PMID: 20142194BACKGROUND
  • Chen GC, Lu XM, Song YM, Gyawail L, Geng ZH, Song MB, Qian DH, Zhang YP, Ni DC, He Y. A 3-year experience of a simple, novel technique for accurate ostial/non-ostial coronary stenting: The buddy balloon anchor stent technique. Catheter Cardiovasc Interv. 2018 Nov 15;92(6):1147-1152. doi: 10.1002/ccd.27667. Epub 2018 Jul 18.

    PMID: 30019847BACKGROUND
  • Yang ZK, Hu J, Ding FH, Ni JW, Zhang RY, Shen WF. One-year outcome of single-stent crossover versus accurate ostial stenting for isolated left anterior descending ostial stenosis. Coron Artery Dis. 2022 Jan 1;31(1):e67-e72. doi: 10.1097/MCA.0000000000001071.

    PMID: 34010192BACKGROUND
  • Elkhateeb O, Thambi S, Beydoun H, Bishop H, Quraishi A, Kidwai B, Title L. Long-term outcomes following ostial left anterior descending artery intervention with or without crossover to left-main. Am J Cardiovasc Dis. 2022 Apr 15;12(2):73-80. eCollection 2022.

    PMID: 35600287BACKGROUND
  • Vaquerizo B, Fernandez-Nofreiras E, Oategui I, Suarez de Lezo J, Rumoroso JR, Martin P, Routledge H, Tizon-Marcos H. Second-Generation Drug-Eluting Balloon for Ostial Side Branch Lesions (001-Bifurcations): Mid-Term Clinical and Angiographic Results. J Interv Cardiol. 2016 Jun;29(3):285-92. doi: 10.1111/joic.12292.

    PMID: 27245124BACKGROUND
  • Erdogan E, Li Z, Zhu YX, Tufaro V, Feng SL, Li Q, Liang L, Chang S, Bu LT, Liu B, Zhou QH, Yap NAL, Bourantas CV, Zhang YJ. DCB combined with provisional DES implantation in the treatment of De Novo Medina 0,1,0 or 0,0,1 left main coronary bifurcation lesions: A proof-of-concept study. Anatol J Cardiol. 2022 Mar;26(3):218-225. doi: 10.5152/AnatolJCardiol.2021.1157.

    PMID: 35346908BACKGROUND

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Yaojun Zhang, Dr

    Xuzhou Third People's Hospital

    STUDY CHAIR

Central Study Contacts

Yaojun Zhang, Dr

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2023

First Posted

December 12, 2023

Study Start

April 22, 2024

Primary Completion

March 1, 2026

Study Completion

March 1, 2026

Last Updated

March 27, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share